首页> 外文期刊>BMC Pregnancy and Childbirth >Effects of antenatal corticosteroids in twin neonates with late preterm birth (ACTWIN [Antenatal Corticosteroids in TWIN late preterm neonates] trial): study protocol for a randomized controlled trial
【24h】

Effects of antenatal corticosteroids in twin neonates with late preterm birth (ACTWIN [Antenatal Corticosteroids in TWIN late preterm neonates] trial): study protocol for a randomized controlled trial

机译:晚期早产的产前病变细胞质的作用(Actwin [双晚早产新生儿的抗试剂类固醇]试验):随机对照试验的研究方案

获取原文
           

摘要

Antenatal corticosteroids have been proven to prevent adverse outcomes including respiratory morbidities in preterm neonates before 34?weeks of gestation. Recently, it has been suggested that antenatal corticosteroids may also be effective in singleton late preterm pregnancies, and guidelines recommend the use of corticosteroids in singleton pregnant women who are at risk for late preterm birth. On the contrary, there is a paucity of information regarding the effectiveness of corticosteroids in twin neonates with late preterm birth. This study aims to determine the effectiveness of antenatal corticosteroids in late preterm twin neonates. In this multicentre randomized controlled trial, women who are at risk for late preterm birth will be enrolled at 34 0/7 to 36 5/7?weeks of gestation. The participants will be randomly assigned to receive antenatal corticosteroids (betamethasone 12?mg, 3?mL intramuscularly [IM]) or placebo (normal saline 3?mL IM). The perinatal outcomes will be compared between the two groups of cases. The primary outcome is severe respiratory complications (the use of continuous positive airway pressure or high-flow nasal cannula for at least 12?h, supplemental oxygen administration with a fraction of oxygen 0.3 or more for at least 24?h, mechanical ventilation, or extracorporeal membranes oxygenation) or perinatal death within the first 72?h of delivery. The secondary outcomes are neonatal mortality and/or other neonatal morbidities. This study will be the first randomized controlled trial that evaluates the effectiveness of antenatal corticosteroids in late preterm twin neonates. NCT03547791 (ClinicalTrials.gov), first submitted date: March 29, 2018, first posted date: June 6, 2018 (retrospectively registered).
机译:已经证明产前皮质类固醇以防止在34个妊娠期之前的早产新生儿中的不良结果,包括呼吸状病病症。最近,有人提出,产前皮质类固醇也可能在单身后早产妊娠中有效,并准则建议使用皮质类固醇在单身孕妇中,这些孕妇出现患有晚期早产的危险。相反,缺乏关于孪生新生儿的皮质类固醇的有效性的信息,具有晚期早产。本研究旨在确定晚期早产孪生新生儿的产前皮质类固醇的有效性。在这种多期式随机对照试验中,有延迟早产风险的女性将在妊娠期34 0/7到36 5/7?周数。将随机分配参与者接受产前皮质类固醇(β塞酮12?Mg,3?ml肌肉内[IM])或安慰剂(正常盐水3?ML IM)。将在两组病例之间进行围产期结果。主要结果是严重的呼吸并发症(使用连续的正气道压力或高流量鼻腔套管至少12〜H,补充氧给药,氧气的一部分0.3或更高,至少24ΩH,机械通气或体外膜氧合)或围产期死亡在第一72℃的递送。二次结果是新生儿死亡率和/或其他新生儿病症。本研究将是第一个随机对照试验,评估晚期早产儿的产前皮质类固醇的有效性。 NCT03547791(ClinicalTrials.gov),首次提交日期:2018年3月29日,第一次发布日期:2018年6月6日(回顾性登记)。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号